Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 234

1.

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.

Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR.

Open Forum Infect Dis. 2017 Jan 19;4(1):ofw274. doi: 10.1093/ofid/ofw274. eCollection 2017 Winter.

2.

Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Doernberg SB, Lodise TP, Thaden JT, Munita JM, Cosgrove SE, Arias CA, Boucher HW, Corey GR, Lowy FD, Murray B, Miller LG, Holland TL; Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG)..

Clin Infect Dis. 2017 Mar 15;64(suppl_1):S24-S29. doi: 10.1093/cid/ciw828.

PMID:
28350900
3.

Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis.

Pericàs JM, Messina JA, Garcia-de-la-Mària C, Park L, Sharma-Kuinkel BK, Marco F, Wray D, Kanafani ZA, Carugati M, Durante-Mangoni E, Tattevin P, Chu VH, Moreno A, Fowler VG Jr, Miró JM; International Collaboration on Endocarditis Microbiology Investigators..

Clin Microbiol Infect. 2017 Feb 1. pii: S1198-743X(17)30050-2. doi: 10.1016/j.cmi.2017.01.017. [Epub ahead of print]

PMID:
28159672
4.

Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates.

Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere SL.

Diagn Microbiol Infect Dis. 2017 Mar;87(3):268-271. doi: 10.1016/j.diagmicrobio.2016.12.009. Epub 2016 Dec 14.

5.

A randomized, blinded, multicenter trial of a gentamicin vancomycin gel (DFA-02) in patients undergoing abdominal surgery.

Bennett-Guerrero E, Berry SM, Bergese SD, Fleshner PR, Minkowitz HS, Segura-Vasi AM, Itani KM, Henderson KW, Rackowski FP, Aberle LH, Stryjewski ME, Corey GR, Allenby KS.

Am J Surg. 2016 Nov 18. pii: S0002-9610(16)30866-2. doi: 10.1016/j.amjsurg.2016.10.007. [Epub ahead of print]

PMID:
27989501
6.

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

Corey GR, Arhin FF, Wikler MA, Sahm DF, Kreiswirth BN, Mediavilla JR, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O'Riordan W; SOLO I, SOLO II Investigators..

Int J Antimicrob Agents. 2016 Nov;48(5):528-534. doi: 10.1016/j.ijantimicag.2016.07.019. Epub 2016 Sep 13.

PMID:
27665522
7.
8.

A randomized, double-blind, placebo controlled safety, tolerability, and pharmacokinetic dose escalation study of a gentamicin vancomycin gel in patients undergoing colorectal surgery.

Bennett-Guerrero E, Minkowitz HS, Segura-Vasi AM, Marcet JE, White JA, Corey GR, Allenby KS.

Perioper Med (Lond). 2016 Jun 16;5:17. doi: 10.1186/s13741-016-0043-2. eCollection 2016.

9.

Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis.

Park LP, Chu VH, Peterson G, Skoutelis A, Lejko-Zupa T, Bouza E, Tattevin P, Habib G, Tan R, Gonzalez J, Altclas J, Edathodu J, Fortes CQ, Siciliano RF, Pachirat O, Kanj S, Wang A; International Collaboration on Endocarditis (ICE) Investigators..

J Am Heart Assoc. 2016 Apr 18;5(4):e003016. doi: 10.1161/JAHA.115.003016.

10.

An Approach to Improve the Negative Predictive Value and Clinical Utility of Transthoracic Echocardiography in Suspected Native Valve Infective Endocarditis.

Sivak JA, Vora AN, Navar AM, Schulte PJ, Crowley AL, Kisslo J, Corey GR, Liao L, Wang A, Velazquez EJ, Samad Z.

J Am Soc Echocardiogr. 2016 Apr;29(4):315-22. doi: 10.1016/j.echo.2015.12.009. Epub 2016 Feb 3.

PMID:
26850679
11.

A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response.

Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, Corey GR, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW.

Clin Trials. 2016 Feb;13(1):22-30. doi: 10.1177/1740774515621721. Epub 2016 Jan 14.

PMID:
26768569
12.

Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.

Johnson JA, Feeney ER, Kubiak DW, Corey GR.

Open Forum Infect Dis. 2015 Oct 29;2(4):ofv156. doi: 10.1093/ofid/ofv156. eCollection 2015 Dec.

13.

Building Sustainable Capacity for Cardiovascular Care at a Public Hospital in Western Kenya.

Binanay CA, Akwanalo CO, Aruasa W, Barasa FA, Corey GR, Crowe S, Esamai F, Einterz R, Foster MC, Gardner A, Kibosia J, Kimaiyo S, Koech M, Korir B, Lawrence JE, Lukas S, Manji I, Maritim P, Ogaro F, Park P, Pastakia SD, Sugut W, Vedanthan R, Yanoh R, Velazquez EJ, Bloomfield GS.

J Am Coll Cardiol. 2015 Dec 8;66(22):2550-60. doi: 10.1016/j.jacc.2015.09.086. Review.

14.

An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection.

Kauf TL, McKinnon P, Corey GR, Bedolla J, Riska PF, Sims M, Jauregui-Peredo L, Friedman B, Hoehns JD, Mercier RC, Garcia-Diaz J, Brenneman SK, Ng D, Lodise T.

BMC Infect Dis. 2015 Nov 7;15:503. doi: 10.1186/s12879-015-1261-9.

15.

Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.

Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, Corey GR, Barriere SL.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S87-93. doi: 10.1093/cid/civ536.

PMID:
26316562
16.

Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.

Pushkin R, Barriere SL, Wang W, Corey GR, Stryjewski ME.

Antimicrob Agents Chemother. 2015 Oct;59(10):6170-4. doi: 10.1128/AAC.00471-15. Epub 2015 Jul 27.

17.

New developments in the management of severe skin and deep skin structure infections - focus on tedizolid.

Durkin MJ, Corey GR.

Ther Clin Risk Manag. 2015 May 22;11:857-62. doi: 10.2147/TCRM.S64553. eCollection 2015. Review.

18.

Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis.

Thom H, Thompson JC, Scott DA, Halfpenny N, Sulham K, Corey GR.

Curr Med Res Opin. 2015 Aug;31(8):1539-51. doi: 10.1185/03007995.2015.1058248. Epub 2015 Jun 30. Review.

PMID:
26038985
19.

Reply to Solnick.

Corey GR, Stryjewski ME.

Clin Infect Dis. 2015 Aug 1;61(3):485-6. doi: 10.1093/cid/civ372. Epub 2015 May 8. No abstract available.

PMID:
25956892
20.

A closer inspection of tedizolid - authors' reply.

Prokocimer P, Corey GR, Das AF, Moran GJ.

Lancet Infect Dis. 2015 Apr;15(4):375. doi: 10.1016/S1473-3099(15)70103-9. No abstract available.

PMID:
25809888

Supplemental Content

Loading ...
Support Center